70 | N | N | N | Moricizine hydrochloride
| KCNK5: potassium channel, subfamily K, member 5 | 0.43243 | Dyclonine hydrochloride
| 0.013225 | SCN9A: sodium channel, voltage-gated, type IX, alpha subunit |
74 | N | N | N | Amiloride hydrochloride
| SCN4B | 0.26923 | Riluzole
| 0.025789 | ACCN1: amiloride-sensitive cation channel 1, neuronal |
83 | N | N | N | Amiloride hydrochloride
| SCN7A: sodium channel, voltage-gated, type VII, alpha | 0.26923 | Riluzole
| 0.087772 | CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit |
92 | N | N | N | Amiloride hydrochloride
| SCN1B: sodium channel, voltage-gated, type I, beta | 0.26923 | Riluzole
| 0.024163 | ACCN3: amiloride-sensitive cation channel 3 |
95 | N | N | N | Amiloride hydrochloride
| SCN3B: sodium channel, voltage-gated, type III, beta | 0.26923 | Riluzole
| 0.024794 | ACCN1: amiloride-sensitive cation channel 1, neuronal |
110 | N | N | N | Phenytoin
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.37500 | Dizocilpine maleate
| 0.022827 | SCN4B |
111 | N | N | N | Verapamil
| GRIA3: glutamate receptor, ionotrophic, AMPA 3 | 0.20000 | Riluzole
| 0.026689 | KCNE1: potassium voltage-gated channel, Isk-related family, member 1 |
114 | N | N | N | Verapamil
| GRIA4: glutamate receptor, ionotrophic, AMPA 4 | 0.20000 | Riluzole
| 0.026577 | KCNE1: potassium voltage-gated channel, Isk-related family, member 1 |
117 | N | N | N | Flecainide acetate
| KCNK5: potassium channel, subfamily K, member 5 | 0.38461 | Dyclonine hydrochloride
| 0.030801 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
150 | N | N | N | Lamotrigine
| KCNK5: potassium channel, subfamily K, member 5 | 0.30435 | Diazoxide
| 0.013225 | SCN9A: sodium channel, voltage-gated, type IX, alpha subunit |
164 | N | N | N | Diazoxide
| GRID2: glutamate receptor, ionotropic, delta 2 | 0.38095 | Riluzole
| 0.19653 | GRIA2: glutamate receptor, ionotropic, AMPA 2 |
176 | N | N | N | Doxorubicin hydrochloride
| CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.23729 | Glyburide
| 0.0043818 | RYR2: ryanodine receptor 2 (cardiac) |
189 | N | N | N | Kainic acid hydrate
| GRID2: glutamate receptor, ionotropic, delta 2 | 0 | Riluzole
| 0.20292 | GRIK2: glutamate receptor, ionotropic, kainate 2 |
194 | N | N | N | Verapamil
| GRIA2: glutamate receptor, ionotropic, AMPA 2 | 0.20000 | Riluzole
| 0.027448 | KCNE1: potassium voltage-gated channel, Isk-related family, member 1 |
206 | N | N | N | Doxorubicin hydrochloride
| KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | 0.24624 | Ketoconazole
| 0.0071212 | RYR2: ryanodine receptor 2 (cardiac) |
208 | N | N | N | Streptomycin sulfate
| CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.066667 | Glyburide
| 0.0043818 | RYR2: ryanodine receptor 2 (cardiac) |
210 | N | N | N | Verapamil
| MCOLN1: mucolipin 1 | 0.085106 | Amiloride hydrochloride
| 0.032255 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
217 | N | N | N | Haloperidol
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.42492 | Thioridazine hydrochloride
| 0.015023 | GRIN2C: glutamate receptor, ionotropic, N-methyl D-aspartate 2C |
219 | N | N | N | Halothane
| RYR2: ryanodine receptor 2 (cardiac) | 0.078947 | Pimozide
| 0.021708 | ITPR3: inositol 1,4,5-trisphosphate receptor, type 3 |
222 | N | N | N | Verapamil
| TRPC6: transient receptor potential cation channel, subfamily C, member 6 | 0.085106 | Amiloride hydrochloride
| 0.027859 | KCNS2: potassium voltage-gated channel, delayed-rectifier, subfamily S, member 2 |
224 | N | N | N | Halothane
| RYR3 | 0.078947 | Pimozide
| 0.021825 | ITPR3: inositol 1,4,5-trisphosphate receptor, type 3 |
228 | N | N | N | Riluzole
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.45833 | Hydroflumethiazide
| 0.016547 | SCN1B: sodium channel, voltage-gated, type I, beta |
229 | N | N | N | Ethosuximide
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.47059 | Butabarbital
| 0.011438 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
256 | N | N | N | Verapamil
| CLCN2: chloride channel 2 | 0.11111 | Lubiprostone
| 0.022598 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
262 | N | N | N | Verapamil
| CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.29412 | Glyburide
| 0.15287 | ABCC9: ATP-binding cassette, sub-family C (CFTR/MRP), member 9 |
281 | N | N | N | Streptomycin sulfate
| KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | 0.075630 | Verapamil
| 0.0071212 | RYR2: ryanodine receptor 2 (cardiac) |
288 | N | N | N | Propofol
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.22727 | Diazoxide
| 0.018959 | GLRA1: glycine receptor, alpha 1 |
301 | N | N | N | Halothane
| RYR1: ryanodine receptor 1 (skeletal) | 0.078947 | Pimozide
| 0.021654 | ITPR1: inositol 1,4,5-trisphosphate receptor, type 1 |
310 | N | N | N | Ketamine hydrochloride
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.38710 | Thioridazine hydrochloride
| 0.024001 | GABRA6: gamma-aminobutyric acid (GABA) A receptor, alpha 6 |
329 | N | N | N | Propofol
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.26471 | Diltiazem hydrochloride
| 0.019626 | GABRD: gamma-aminobutyric acid (GABA) A receptor, delta |
336 | N | N | N | Magnesium sulfate
| CACNA2D4: calcium channel, voltage-dependent, alpha 2/delta subunit 4 | 0.027027 | Nifedipine
| 0.19447 | CACNA2D1: calcium channel, voltage-dependent, alpha 2/delta subunit 1 |
343 | N | N | N | Paramethadione
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.30435 | Methohexital
| 0.011438 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
354 | N | N | N | Verapamil
| CHRND: cholinergic receptor, nicotinic, delta | 0.29268 | Metoclopramide
| 0.029958 | KCNE3: potassium voltage-gated channel, Isk-related family, member 3 |
360 | N | N | N | Verapamil
| GRID2: glutamate receptor, ionotropic, delta 2 | 0.20000 | Riluzole
| 0.020345 | KCNE1L: KCNE1-like |
363 | N | N | N | Dofetilide
| KCNK6: potassium channel, subfamily K, member 6 | 0.41270 | Ibutilide fumarate
| 0.19314 | KCNK2: potassium channel, subfamily K, member 2 |
369 | N | N | N | Verapamil
| P2RX2: purinergic receptor P2X, ligand-gated ion channel, 2 | 0.17500 | Caffeine
| 0.042682 | KCNK4: potassium channel, subfamily K, member 4 |
370 | N | N | N | Diazoxide
| CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.27027 | Glyburide
| 0.14579 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
371 | N | N | N | Flecainide acetate
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.27027 | Riluzole
| 0.015652 | KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 |
374 | N | N | N | Verapamil
| CHRNB1: cholinergic receptor, nicotinic, beta 1 (muscle) | 0.29268 | Metoclopramide
| 0.035142 | KCNK4: potassium channel, subfamily K, member 4 |
375 | N | N | N | Indapamide
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.42857 | Benzthiazide
| 0.022575 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
376 | N | N | N | Amlexanox
| CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.38235 | Caffeine and sodium benzoate
| 0.14579 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
381 | N | N | N | Tolbutamide
| CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.41667 | Glyburide
| 0.14579 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
386 | N | N | N | Levetiracetam
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.26087 | Ketamine hydrochloride
| 0.0099594 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
391 | N | N | N | Diazoxide
| CLCN2: chloride channel 2 | 0.051282 | Lubiprostone
| 0.022598 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
392 | N | N | N | Verapamil
| SLC6A14: solute carrier family 6 (amino acid transporter), member 14 | 0 | Proline
| 0.033290 | KCNK17: potassium channel, subfamily K, member 17 |
394 | N | N | N | Ibutilide fumarate
| CACNA2D4: calcium channel, voltage-dependent, alpha 2/delta subunit 4 | 0.29167 | Verapamil
| 0.19447 | CACNA2D1: calcium channel, voltage-dependent, alpha 2/delta subunit 1 |
397 | N | N | N | Ethosuximide
| CACNA1E: calcium channel, voltage-dependent, R type, alpha 1E subunit | 0.15790 | Gabapentin
| 0.12631 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
399 | N | N | N | Amlexanox
| KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.37500 | Repaglinide
| 0.013742 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
401 | N | N | N | Verapamil
| SLC6A7: solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 | 0 | Proline
| 0.031499 | KCNK16: potassium channel, subfamily K, member 16 |
410 | N | N | N | Encainide hydrochloride
| KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 | 0.47059 | Bupivacaine hydrochloride
| 0.016875 | SCN4A: sodium channel, voltage-gated, type IV, alpha subunit |
417 | N | N | N | Verapamil
| GLRA3 | 0.14583 | Tropisetron hydrochloride
| 0.029733 | KCNE1L: KCNE1-like |
421 | N | N | N | Penfluridol
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.48936 | Astemizole
| 0.013728 | CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit |
432 | N | N | N | Lubiprostone
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.25926 | Penicillin G procaine
| 0.013899 | CLCN2: chloride channel 2 |
433 | N | N | N | Verapamil
| SLC6A1: solute carrier family 6 (neurotransmitter transporter, GABA), member 1 | 0.12245 | Cocaine
| 0.033720 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 |
440 | N | N | N | Diazoxide
| MCOLN1: mucolipin 1 | 0.18518 | Amiloride hydrochloride
| 0.032255 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
445 | N | N | N | Diazoxide
| TRPC6: transient receptor potential cation channel, subfamily C, member 6 | 0.18518 | Amiloride hydrochloride
| 0.027859 | KCNS2: potassium voltage-gated channel, delayed-rectifier, subfamily S, member 2 |
456 | N | N | N | Dopamine hydrochloride
| GLRA3 | 0.21429 | Tropisetron hydrochloride
| 0.095753 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
462 | N | N | N | Verapamil
| P2RX7: purinergic receptor P2X, ligand-gated ion channel, 7 | 0.17500 | Caffeine
| 0.027427 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
466 | N | N | N | Ondansetron hydrochloride hydrate
| GLRA3 | 0.34286 | Tropisetron hydrochloride
| 0.095753 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
468 | N | N | N | Trifluoperazine maleate
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.45833 | Thioridazine hydrochloride
| 0.030674 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
470 | N | N | N | Benzocaine
| CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit | 0.31034 | Nitrendipine
| 0.12677 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
474 | N | N | N | Benzocaine
| CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit | 0.31034 | Nitrendipine
| 0.12915 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
479 | N | N | N | Trimethadione
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.28571 | Hexobarbital
| 0.0087226 | CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit |
486 | N | N | N | Dantrolene
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.41935 | Clobazam
| 0.0064074 | RYR1: ryanodine receptor 1 (skeletal) |
487 | N | N | N | Cetiedil citrate
| CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.20690 | Glyburide
| 0.010929 | KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
490 | N | N | N | Disopyramide
| CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit | 0.34884 | Verapamil
| 0.13120 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
492 | N | N | N | Ketoconazole
| CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.40816 | Glyburide
| 0.011075 | KCNA10: potassium voltage-gated channel, shaker-related subfamily, member 10 |
495 | N | N | N | Diazoxide
| SCN4B | 0.40000 | Zonisamide
| 0.044678 | KCNE1: potassium voltage-gated channel, Isk-related family, member 1 |
501 | N | N | N | Cetiedil citrate
| CHRNA2 | 0.33962 | Nicotine bitartrate
| 0.019239 | KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
503 | N | N | N | Riluzole
| GRIN1: glutamate receptor, ionotropic, N-methyl D-aspartate 1 | 0.23077 | Ketamine hydrochloride
| 0.15710 | GRIK1: glutamate receptor, ionotropic, kainate 1 |
506 | N | N | N | Verapamil
| P2RX5: purinergic receptor P2X, ligand-gated ion channel, 5 | 0.17500 | Caffeine
| 0.045889 | KCNE1L: KCNE1-like |
516 | N | N | N | Disopyramide
| CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit | 0.34884 | Verapamil
| 0.13386 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
517 | N | N | N | Mefloquine hydrochloride
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.31250 | Riluzole
| 0.011082 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
518 | N | N | N | Glyburide
| KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | 0.40816 | Ketoconazole
| 0.017942 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
520 | N | N | N | Diazepam
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.30769 | Diazoxide
| 0.018959 | GLRA1: glycine receptor, alpha 1 |
524 | Y | Y | Y | Repaglinide
| ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 | 0.43478 | Glyburide
| 0.013742 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
525 | N | N | N | Ibutilide fumarate
| KCNK16: potassium channel, subfamily K, member 16 | 0.29167 | Verapamil
| 0.24996 | KCNK6: potassium channel, subfamily K, member 6 |
527 | N | N | N | Zonisamide
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.40000 | Diazoxide
| 0.016547 | SCN1B: sodium channel, voltage-gated, type I, beta |
528 | N | N | N | Verapamil
| P2RX3: purinergic receptor P2X, ligand-gated ion channel, 3 | 0.17500 | Caffeine
| 0.030341 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
533 | N | N | N | Amlodipine maleate
| CACNG1: calcium channel, voltage-dependent, gamma subunit 1 | 0.48837 | Nisoldipine
| 0.018083 | CACNA1F: calcium channel, voltage-dependent, L type, alpha 1F subunit |
535 | N | N | N | Halazepam
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.39286 | Riluzole
| 0.011445 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
537 | N | N | N | Amlodipine besylate
| CACNG1: calcium channel, voltage-dependent, gamma subunit 1 | 0.48837 | Nitrendipine
| 0.018083 | CACNA1F: calcium channel, voltage-dependent, L type, alpha 1F subunit |
539 | N | N | N | Verapamil
| P2RX6: purinergic receptor P2X, ligand-gated ion channel, 6 | 0.17500 | Caffeine
| 0.029220 | KCNE3: potassium voltage-gated channel, Isk-related family, member 3 |
544 | N | N | N | Diazoxide
| CHRND: cholinergic receptor, nicotinic, delta | 0.25926 | Metoclopramide
| 0.029958 | KCNE3: potassium voltage-gated channel, Isk-related family, member 3 |
546 | N | N | N | Dequalinium chloride
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.34783 | Thioridazine hydrochloride
| 0.032967 | KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 |
547 | N | N | N | Verapamil
| GABRR2 | 0.30233 | Zaleplon
| 0.030883 | KCNE1L: KCNE1-like |
555 | N | N | N | Mefloquine hydrochloride
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.47500 | Flecainide acetate
| 0.081115 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
560 | N | N | N | Pramoxine hydrochloride
| KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 | 0.38461 | Flecainide acetate
| 0.026637 | KCNK5: potassium channel, subfamily K, member 5 |
561 | N | Y | Y | Nateglinide
| ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 | 0.36585 | Glyburide
| 0.013742 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
563 | N | N | N | Verapamil
| P2RX1: purinergic receptor P2X, ligand-gated ion channel, 1 | 0.17500 | Caffeine
| 0.045455 | KCNE3: potassium voltage-gated channel, Isk-related family, member 3 |
564 | N | N | N | Exemestane
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.34483 | Hexobarbital
| 0.090264 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) |
565 | N | N | N | Riluzole
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.38095 | Diazoxide
| 0.025836 | SCN4A: sodium channel, voltage-gated, type IV, alpha subunit |
570 | N | Y | N | Magnesium sulfate
| CACNB2: calcium channel, voltage-dependent, beta 2 subunit | 0.027027 | Nifedipine
| 0.015801 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 |
577 | N | N | N | Cyproheptadine hydrochloride
| CHRNA2 | 0.39317 | Tubocurarine chloride
| 0.018097 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
581 | N | N | N | Zonisamide
| CACNA1E: calcium channel, voltage-dependent, R type, alpha 1E subunit | 0.22222 | Phenytoin
| 0.12631 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
582 | N | N | N | Dofetilide
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.41026 | Benzthiazide
| 0.022874 | KCNK2: potassium channel, subfamily K, member 2 |
583 | N | N | N | Ibutilide fumarate
| KCNK2: potassium channel, subfamily K, member 2 | 0.41270 | Dofetilide
| 0.20401 | KCNK1: potassium channel, subfamily K, member 1 |
590 | N | N | N | Diazoxide
| CHRNB1: cholinergic receptor, nicotinic, beta 1 (muscle) | 0.25926 | Metoclopramide
| 0.035142 | KCNK4: potassium channel, subfamily K, member 4 |
596 | N | N | N | Magnesium sulfate
| KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 | 0.10345 | Glyclopyramide
| 0.025831 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 |
600 | N | N | N | Letrozole
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.34884 | Ketoconazole
| 0.017956 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) |
604 | N | N | N | Granisetron
| KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.48387 | Nateglinide
| 0.017658 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
606 | N | N | N | Diazoxide
| SCN3B: sodium channel, voltage-gated, type III, beta | 0.40000 | Zonisamide
| 0.046014 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
610 | N | N | N | Dequalinium chloride
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.40000 | Halofantrine hydrochloride
| 0.017196 | KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 |
620 | N | N | N | Diazepam
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.38889 | Diltiazem hydrochloride
| 0.019626 | GABRD: gamma-aminobutyric acid (GABA) A receptor, delta |
626 | N | N | N | Diazoxide
| SLC6A1: solute carrier family 6 (neurotransmitter transporter, GABA), member 1 | 0.16129 | Cocaine
| 0.026833 | KCND2: potassium voltage-gated channel, Shal-related subfamily, member 2 |
633 | N | N | N | Benzocaine
| CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit | 0.31034 | Nitrendipine
| 0.13951 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
637 | N | N | N | Verapamil
| P2RX4: purinergic receptor P2X, ligand-gated ion channel, 4 | 0.17500 | Caffeine
| 0.033352 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
641 | N | N | N | Diazoxide
| SCN1B: sodium channel, voltage-gated, type I, beta | 0.40000 | Zonisamide
| 0.045507 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
647 | N | N | N | Halofantrine hydrochloride
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.38636 | Flurazepam
| 0.012494 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 |
649 | N | N | N | Phentermine
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.38889 | Mexiletine hydrochloride
| 0.010278 | SLC6A3: solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
650 | N | N | N | Dyclonine hydrochloride
| KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 | 0.45161 | Bupivacaine hydrochloride
| 0.026637 | KCNK5: potassium channel, subfamily K, member 5 |
651 | N | N | N | Diazoxide
| P2RX2: purinergic receptor P2X, ligand-gated ion channel, 2 | 0.21739 | Caffeine
| 0.042682 | KCNK4: potassium channel, subfamily K, member 4 |
656 | N | N | N | Nateglinide
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.44828 | Mepivacaine hydrochloride
| 0.0099976 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
664 | N | N | N | Riluzole
| CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit | 0.26923 | Amiloride hydrochloride
| 0.13120 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
667 | N | N | N | Bepridil hydrochloride
| SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 | 0.45714 | Trimipramine
| 0.014048 | KCNQ4: potassium voltage-gated channel, KQT-like subfamily, member 4 |
669 | N | N | N | Disopyramide
| CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit | 0.34884 | Verapamil
| 0.13951 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
682 | N | N | N | Amlexanox
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.38710 | Furosemide
| 0.010906 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
683 | N | N | N | Benzocaine
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.45000 | Felbamate
| 0.022827 | SCN4B |
685 | N | N | N | Phenacemide
| KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.38461 | Nateglinide
| 0.011295 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
691 | N | N | N | Mefloquine hydrochloride
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.31707 | Bendroflumethiazide
| 0.022575 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
695 | N | N | N | Diazoxide
| SCN4A: sodium channel, voltage-gated, type IV, alpha subunit | 0.40000 | Zonisamide
| 0.030864 | KCNV1: potassium channel, subfamily V, member 1 |
698 | N | Y | N | Magnesium sulfate
| CACNB1: calcium channel, voltage-dependent, beta 1 subunit | 0.042857 | Ibutilide fumarate
| 0.016265 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 |
703 | N | N | N | Codeine sulfate
| KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 | 0.39744 | Quinine sulfate
| 0.015233 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
704 | N | N | N | Verapamil
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.36585 | Profenamine hydrochloride
| 0.023718 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
708 | N | N | N | Mefloquine hydrochloride
| GLRA1: glycine receptor, alpha 1 | 0.32432 | Tropisetron hydrochloride
| 0.015107 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
709 | N | N | N | Felbamate
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.18518 | Riluzole
| 0.092521 | GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A |
713 | N | N | N | Azimilide dihydrochloride
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.38636 | Flurazepam
| 0.015344 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
716 | N | N | N | Ethchlorvynol
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.21429 | Methoxyflurane
| 0.011445 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
722 | N | N | N | Verapamil
| HTR3D: 5-hydroxytryptamine (serotonin) receptor 3 family member D | 0.23404 | Ondansetron hydrochloride hydrate
| 0.042488 | KCNMB1: potassium large conductance calcium-activated channel, subfamily M, beta member 1 |
726 | N | Y | N | Amlodipine besylate
| CACNB2: calcium channel, voltage-dependent, beta 2 subunit | 0.48837 | Nitrendipine
| 0.017211 | CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
733 | N | N | N | Diazoxide
| SLC6A14: solute carrier family 6 (amino acid transporter), member 14 | 0 | Proline
| 0.033290 | KCNK17: potassium channel, subfamily K, member 17 |
738 | N | N | N | Fluphenazine maleate
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.48837 | Thioridazine hydrochloride
| 0.024221 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
740 | N | N | N | Ethosuximide
| CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) | 0.44444 | Pentobarbital
| 0.0094499 | CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit |
745 | N | N | N | Dopamine hydrochloride
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.35294 | Chlorzoxazone
| 0.015696 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
748 | N | N | N | Mefloquine hydrochloride
| KCNE1: potassium voltage-gated channel, Isk-related family, member 1 | 0.24390 | Indapamide
| 0.026945 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
751 | N | N | N | Diazoxide
| GRIN1: glutamate receptor, ionotropic, N-methyl D-aspartate 1 | 0.29167 | Ketamine hydrochloride
| 0.14656 | GRIA1: glutamate receptor, ionotropic, AMPA 1 |
752 | N | N | N | Maprotiline
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.45714 | Moricizine
| 0.0094747 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
753 | N | N | N | Nicotine bitartrate
| KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 | 0.24490 | Quinine hydrochloride hydrate
| 0.18777 | KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 |
758 | N | N | N | Sumatriptan
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.36000 | Diazoxide
| 0.015696 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
761 | N | N | N | Dofetilide
| CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit | 0.41270 | Ibutilide fumarate
| 0.011007 | KCNH5: potassium voltage-gated channel, subfamily H (eag-related), member 5 |
764 | N | Y | N | Quinidine sulfate
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.32836 | Astemizole
| 0.22326 | KCNH1: potassium voltage-gated channel, subfamily H (eag-related), member 1 |
765 | N | Y | N | Amlodipine maleate
| CACNB2: calcium channel, voltage-dependent, beta 2 subunit | 0.48837 | Nisoldipine
| 0.017211 | CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
768 | N | N | N | Mibefradil dihydrochloride
| PKD1: polycystic kidney disease 1 (autosomal dominant) | 0.44898 | Verapamil
| 0.0049566 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
770 | N | N | N | Diazoxide
| P2RX7: purinergic receptor P2X, ligand-gated ion channel, 7 | 0.21739 | Caffeine
| 0.027427 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
772 | N | N | N | Nortriptyline hydrochloride
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.48387 | Dizocilpine maleate
| 0.024221 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
775 | N | N | N | Mibefradil dihydrochloride
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.44898 | Verapamil
| 0.13474 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
776 | N | N | N | Diazoxide
| SLC6A7: solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 | 0 | Proline
| 0.031499 | KCNK16: potassium channel, subfamily K, member 16 |
777 | N | N | N | Propafenone hydrochloride
| KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 | 0.34091 | Verapamil
| 0.21997 | KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 |
778 | N | N | N | Amlodipine besylate
| CACNA2D4: calcium channel, voltage-dependent, alpha 2/delta subunit 4 | 0.48837 | Nitrendipine
| 0.0092209 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
779 | N | N | N | Diazoxide
| GLRA3 | 0.24138 | Tropisetron hydrochloride
| 0.029733 | KCNE1L: KCNE1-like |
780 | N | N | N | Phencyclidine hydrochloride
| KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 | 0.31250 | Bupivacaine hydrochloride
| 0.18777 | KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 |
781 | N | N | N | Dopamine hydrochloride
| GLRA2: glycine receptor, alpha 2 | 0.26087 | Felbamate
| 0.10113 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
788 | N | N | N | Lamotrigine
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.35000 | Chlorzoxazone
| 0.011633 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
790 | N | N | N | Diazoxide
| SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.16129 | Cocaine
| 0.027170 | KCNF1: potassium voltage-gated channel, subfamily F, member 1 |
791 | N | N | N | Penfluridol
| KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | 0.48333 | Trifluoperazine hydrochloride
| 0.011237 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
794 | N | N | N | Paroxetine
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.43590 | Cisapride
| 0.013109 | SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
798 | N | N | N | Zaleplon
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.37143 | Disopyramide
| 0.013396 | GABRE |
802 | N | N | N | Physostigmine sulfate
| KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 | 0.36986 | Quinine sulfate
| 0.015233 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
807 | N | N | N | Diazoxide
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.38095 | Riluzole
| 0.092521 | GRIA1: glutamate receptor, ionotropic, AMPA 1 |
808 | N | N | N | Diazoxide
| ACCN2: amiloride-sensitive cation channel 2, neuronal | 0.18518 | Amiloride hydrochloride
| 0.026659 | KCNE1L: KCNE1-like |
815 | N | N | N | Diazoxide
| ACCN1: amiloride-sensitive cation channel 1, neuronal | 0.18518 | Amiloride hydrochloride
| 0.027845 | KCNE4: potassium voltage-gated channel, Isk-related family, member 4 |
816 | N | N | Y | Bepridil hydrochloride
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.45454 | Terfenadine
| 0.017204 | KCNQ4: potassium voltage-gated channel, KQT-like subfamily, member 4 |
817 | N | N | N | Dibucaine
| KCNK5: potassium channel, subfamily K, member 5 | 0.44828 | Lidocaine
| 0.011241 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
820 | N | N | N | Sertraline
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.48276 | Midazolam
| 0.014964 | SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
822 | N | N | N | Mefloquine hydrochloride
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.30769 | Halazepam
| 0.015344 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
826 | N | N | N | Codeine
| KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 | 0.35294 | Bupivacaine hydrochloride
| 0.020018 | CHRNA10 |
827 | N | N | N | Diltiazem hydrochloride
| KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 | 0.36956 | Verapamil
| 0.22001 | KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 |
830 | N | N | N | Penicillin G procaine
| CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit | 0.47676 | Diltiazem malate
| 0.011266 | GABRA5: gamma-aminobutyric acid (GABA) A receptor, alpha 5 |
834 | N | N | N | Diazoxide
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.40000 | Zonisamide
| 0.025826 | KCNS2: potassium voltage-gated channel, delayed-rectifier, subfamily S, member 2 |
838 | N | N | N | Ibutilide fumarate
| KCNK10: potassium channel, subfamily K, member 10 | 0.29167 | Verapamil
| 0.18687 | KCNK1: potassium channel, subfamily K, member 1 |
839 | N | N | N | Zonisamide
| PKD1: polycystic kidney disease 1 (autosomal dominant) | 0.22222 | Phenytoin
| 0.012238 | SCN1B: sodium channel, voltage-gated, type I, beta |
842 | N | N | N | Dizocilpine maleate
| KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.48387 | Nortriptyline hydrochloride
| 0.024221 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
843 | N | N | N | Amiodarone hydrochloride
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.42105 | Fluoxetine
| 0.021769 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
848 | N | N | N | Promethazine teoclate
| RYR1: ryanodine receptor 1 (skeletal) | 0.40476 | Caffeine and sodium benzoate
| 0.0072515 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
849 | Y | N | N | Diazoxide
| SCN3A: sodium channel, voltage-gated, type III, alpha subunit | 0.40000 | Zonisamide
| 0.025645 | KCNF1: potassium voltage-gated channel, subfamily F, member 1 |
850 | N | N | N | Dyclonine hydrochloride
| KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.43333 | Tolazamide
| 0.021462 | KCNK5: potassium channel, subfamily K, member 5 |
851 | N | N | N | Kainic acid hydrate
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.28125 | Dizocilpine maleate
| 0.096106 | GRIK2: glutamate receptor, ionotropic, kainate 2 |
853 | N | N | N | Dizocilpine maleate
| GRIK2: glutamate receptor, ionotropic, kainate 2 | 0.28125 | Kainic acid hydrate
| 0.15526 | GRIN1: glutamate receptor, ionotropic, N-methyl D-aspartate 1 |
854 | N | N | N | Flurazepam
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.43750 | Chloroprocaine hydrochloride
| 0.012903 | GABRG2: gamma-aminobutyric acid (GABA) A receptor, gamma 2 |
855 | N | N | N | Sumatriptan
| KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.40741 | Tolbutamide
| 0.021953 | HTR3E: 5-hydroxytryptamine (serotonin) receptor 3, family member E |
856 | N | N | N | Amlodipine maleate
| CACNA2D4: calcium channel, voltage-dependent, alpha 2/delta subunit 4 | 0.48837 | Nisoldipine
| 0.0092209 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
858 | N | N | Y | Flecainide acetate
| KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 | 0.34146 | Bupivacaine hydrochloride
| 0.24349 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
860 | N | N | N | Diltiazem hydrochloride
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.44444 | Fluoxetine
| 0.022791 | KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 |
861 | N | N | N | Carbamazepine
| CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit | 0.37037 | Phenytoin
| 0.13120 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
862 | N | N | N | Diazoxide
| P2RX5: purinergic receptor P2X, ligand-gated ion channel, 5 | 0.21739 | Caffeine
| 0.045889 | KCNE1L: KCNE1-like |
865 | N | N | N | Kainic acid hydrate
| SLC6A14: solute carrier family 6 (amino acid transporter), member 14 | 0.33333 | Proline
| 0.015453 | GRIK4: glutamate receptor, ionotropic, kainate 4 |
867 | N | N | N | Sertraline
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.42308 | Ketamine hydrochloride
| 0.010907 | SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
871 | N | N | N | Indapamide
| KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.41026 | Glipizide
| 0.027394 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
872 | N | N | N | Flecainide acetate
| GLRA1: glycine receptor, alpha 1 | 0.25714 | Sevoflurane
| 0.019946 | KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 |
875 | N | N | N | Glyclopyramide
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.37838 | Cisapride
| 0.014705 | KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 |
877 | N | N | N | Mibefradil dihydrochloride
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.44898 | Verapamil
| 0.13545 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
878 | N | N | N | Promethazine teoclate
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.38636 | Flurazepam
| 0.016138 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
881 | N | N | N | Hydroflumethiazide
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.45833 | Riluzole
| 0.0091408 | KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 |
883 | N | N | N | Halazepam
| KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.48387 | Fluoxetine
| 0.016138 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
885 | N | N | N | Nifedipine
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.38235 | Cocaine
| 0.13474 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
886 | N | N | N | Caffeine
| CLCN2: chloride channel 2 | 0.051282 | Lubiprostone
| 0.013935 | P2RX1: purinergic receptor P2X, ligand-gated ion channel, 1 |
887 | N | N | N | Trichlormethiazide
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.40000 | Riluzole
| 0.0091408 | KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 |
889 | N | N | N | Trifluoperazine hydrochloride
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.32353 | Riluzole
| 0.018721 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
893 | N | N | N | Amiloride hydrochloride
| GRID2: glutamate receptor, ionotropic, delta 2 | 0.26923 | Riluzole
| 0.014175 | MCOLN1: mucolipin 1 |
896 | N | N | N | Felbamate
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.45000 | Benzocaine
| 0.010173 | GLRA2: glycine receptor, alpha 2 |
898 | N | N | N | Caffeine
| MCOLN1: mucolipin 1 | 0.14286 | Amiloride hydrochloride
| 0.023510 | P2RX1: purinergic receptor P2X, ligand-gated ion channel, 1 |
900 | N | N | N | Kainic acid hydrate
| SLC6A7: solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 | 0.33333 | Proline
| 0.012768 | GRIK4: glutamate receptor, ionotropic, kainate 4 |
903 | N | N | N | Caffeine
| TRPC6: transient receptor potential cation channel, subfamily C, member 6 | 0.14286 | Amiloride hydrochloride
| 0.016201 | P2RX5: purinergic receptor P2X, ligand-gated ion channel, 5 |
904 | N | N | N | Diazoxide
| P2RX3: purinergic receptor P2X, ligand-gated ion channel, 3 | 0.21739 | Caffeine
| 0.030341 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
909 | N | N | N | Aminoglutethimide
| CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit | 0.42105 | Ethosuximide
| 0.0080876 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) |
910 | N | N | N | Diazoxide
| P2RX6: purinergic receptor P2X, ligand-gated ion channel, 6 | 0.21739 | Caffeine
| 0.029220 | KCNE3: potassium voltage-gated channel, Isk-related family, member 3 |
912 | N | N | N | Halazepam
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.38461 | Diltiazem hydrochloride
| 0.019068 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
914 | N | N | N | Trichlormethiazide
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.36667 | Furosemide
| 0.011447 | KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 |
915 | N | N | N | Riluzole
| CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit | 0.26923 | Amiloride hydrochloride
| 0.13386 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
917 | N | N | N | Azimilide dihydrochloride
| KCNE1: potassium voltage-gated channel, Isk-related family, member 1 | 0.21818 | Verapamil
| 0.026945 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
918 | N | N | N | Flurazepam
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.46154 | Diltiazem hydrochloride
| 0.019626 | GABRD: gamma-aminobutyric acid (GABA) A receptor, delta |
920 | N | N | N | Fluoxetine hydrochloride
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.46875 | Halazepam
| 0.021675 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
921 | N | N | N | Enoxacin hydrate
| KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | 0.30682 | Trifluoperazine maleate
| 0.021832 | GABRA3: gamma-aminobutyric acid (GABA) A receptor, alpha 3 |
927 | N | N | N | Diazoxide
| P2RX1: purinergic receptor P2X, ligand-gated ion channel, 1 | 0.21739 | Caffeine
| 0.045455 | KCNE3: potassium voltage-gated channel, Isk-related family, member 3 |
928 | N | N | N | Amiodarone hydrochloride
| KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.42105 | Fluoxetine
| 0.027535 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
929 | N | N | N | Verapamil
| GRIN2D: glutamate receptor, ionotropic, N-methyl D-aspartate 2D | 0.28261 | Haloperidol
| 0.029109 | KCNK4: potassium channel, subfamily K, member 4 |
932 | N | N | N | Ibutilide fumarate
| KCNK5: potassium channel, subfamily K, member 5 | 0.29167 | Verapamil
| 0.17161 | KCNK1: potassium channel, subfamily K, member 1 |
935 | N | N | N | Bepridil hydrochloride
| KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.47059 | Desipramine hydrochloride
| 0.035737 | KCNQ4: potassium voltage-gated channel, KQT-like subfamily, member 4 |
936 | N | N | N | Doxorubicin hydrochloride
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.30508 | Quinidine gluconate
| 0.0051579 | RYR1: ryanodine receptor 1 (skeletal) |
937 | N | N | N | Diazoxide
| GRIN3B: glutamate receptor, ionotropic, N-methyl-D-aspartate 3B | 0.29167 | Ketamine hydrochloride
| 0.094588 | GRIA2: glutamate receptor, ionotropic, AMPA 2 |
938 | N | N | N | Phencyclidine hydrochloride
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.44444 | Dextromethorphan
| 0.015803 | CHRNA10 |
939 | N | N | N | Propafenone hydrochloride
| KCNK16: potassium channel, subfamily K, member 16 | 0.34091 | Verapamil
| 0.24672 | KCNK5: potassium channel, subfamily K, member 5 |
940 | N | N | N | Indapamide
| KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 | 0.43333 | Glyclopyramide
| 0.029070 | KCNE1: potassium voltage-gated channel, Isk-related family, member 1 |
945 | N | N | N | Codeine
| KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 | 0.38889 | Quinine hydrochloride hydrate
| 0.015233 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
946 | N | N | N | Penicillin G procaine
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.40476 | Procaine hydrochloride
| 0.011567 | GABRA2: gamma-aminobutyric acid (GABA) A receptor, alpha 2 |
947 | N | N | N | Pramoxine hydrochloride
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.42105 | Cisapride
| 0.019783 | KCNK5: potassium channel, subfamily K, member 5 |
953 | N | N | N | Cetiedil citrate
| SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 | 0.31707 | Methylphenidate
| 0.022059 | KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
954 | N | N | N | Quinine sulfate
| CHRNA2 | 0.39744 | Codeine sulfate
| 0.017256 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
955 | Y | N | N | Glyburide
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.45652 | Astemizole
| 0.015300 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
956 | N | N | N | Dofetilide
| KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 | 0.41270 | Ibutilide fumarate
| 0.025318 | KCNK2: potassium channel, subfamily K, member 2 |
958 | N | N | N | Bupivacaine hydrochloride
| KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 | 0.34146 | Flecainide acetate
| 0.22153 | KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 |
963 | N | N | N | Halazepam
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.41667 | Bendroflumethiazide
| 0.011447 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
964 | N | N | N | Amiloride hydrochloride
| SCN3A: sodium channel, voltage-gated, type III, alpha subunit | 0.36000 | Lamotrigine
| 0.12915 | CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit |
965 | N | N | N | Tolbutamide
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.45833 | Lidocaine
| 0.010834 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
967 | N | N | N | Dibucaine
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.40476 | Halofantrine hydrochloride
| 0.0091581 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
971 | N | N | N | Galantamine hydrobromide
| KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 | 0.36111 | Quinine hydrochloride hydrate
| 0.015233 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
973 | N | N | N | Glyclopyramide
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.32000 | Diazoxide
| 0.0097843 | KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 |
976 | N | N | N | Verapamil
| GRIN3B: glutamate receptor, ionotropic, N-methyl-D-aspartate 3B | 0.28261 | Haloperidol
| 0.026014 | KCNE1: potassium voltage-gated channel, Isk-related family, member 1 |
977 | N | N | N | Zonisamide
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.29167 | Felbamate
| 0.022827 | SCN4B |
978 | N | N | N | Carbamazepine
| CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit | 0.37037 | Phenytoin
| 0.13386 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
981 | N | N | N | Caffeine
| KCNK12: potassium channel, subfamily K, member 12 | 0 | Halothane
| 0.019268 | P2RX6: purinergic receptor P2X, ligand-gated ion channel, 6 |
986 | N | N | N | Gallopamil hydrochloride
| CHRNA2 | 0.36508 | Metocurine iodide
| 0.010362 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
988 | N | N | N | Nateglinide
| HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A | 0.48387 | Granisetron
| 0.017658 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
990 | N | N | N | Amiloride hydrochloride
| SCN4A: sodium channel, voltage-gated, type IV, alpha subunit | 0.36000 | Lamotrigine
| 0.11479 | CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit |
992 | N | N | N | Biperiden
| SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 | 0.36364 | Cocaine
| 0.020712 | CHRNA2 |
996 | N | N | N | Kainic acid hydrate
| CLCN2: chloride channel 2 | 0.22857 | Lubiprostone
| 0.012355 | GRIK4: glutamate receptor, ionotropic, kainate 4 |
997 | N | N | N | Prilocaine
| KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.47826 | Tolbutamide
| 0.0099976 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |